Avolve

Quick links to important sections

Avolve

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Avolve

Property Description
Active ingredient Dutasteride (INN)
Form Soft gelatin capsule
Pharmacological class 5α-reductase inhibitor
General purpose Suppression of dihydrotestosterone (DHT)
Origin Synthetic compound (Azasteroid)

What Type of Medicine Is Avolve (Dutasteride)?

Avolve is a systemic, prescription-only pharmaceutical preparation containing the active ingredient Dutasteride. It belongs to the precise pharmacological class known as a 5α-reductase inhibitor, which is a type of enzyme-blocking medication. Dutasteride is a synthetic 4-azasteroid compound created in a laboratory, defining its origin as chemically synthesized. This agent is clinically recognized for providing a comprehensive approach to androgen modulation.

Form, Composition, and General Purpose

The medication Avolve is provided for oral administration as a soft gelatin capsule. This is a single-ingredient product, or monotherapy, with the active substance dissolved within an oil-based vehicle inside the capsule, a formulation designed to aid systemic absorption. The core purpose of Avolve is to achieve a substantial and long-lasting reduction in the body's concentration of dihydrotestosterone (DHT). This specific action is relevant in scenarios involving tissue growth driven by elevated androgen activity.

Dual Action: Distinguishing Avolve's Mechanism

Avolve is uniquely recognized as a dual inhibitor because it potently suppresses both forms of the 5α-reductase enzyme—Type 1 and Type 2. This comprehensive enzyme suppression is Avolve's key differentiating feature, setting it apart from older inhibitors that may only target Type 2. By blocking both enzyme types, Avolve can cause a significant and sustained suppression of circulating DHT levels, thereby providing an effective approach to hormonal modulation.

Regulatory References

  1. Dutasteride SmPC

What side effects are possible with Avolve?

Possible Side Effects and Safety Information

This section outlines the officially documented adverse reactions and safety constraints for Avolve (Dutasteride), as found in government regulatory documents like the FDA Prescribing Information and the EMA Summary of Product Characteristics (SmPC). The information is based strictly on regulatory classifications and statements.

Officially Documented Adverse Reactions

Side effects are categorized by the system-organ class (SOC) affected, with frequency generally based on regulatory standards (e.g., Common: ge 1/100 to <1/10).

System Organ Class Common Reactions Not Known Frequency Reactions
Reproductive system and breast disorders Impotence, decreased libido, ejaculation disorders, breast enlargement/tenderness (gynecomastia) Testicular pain and swelling, persistent sexual dysfunction after discontinuation
Immune system disorders - Allergic reactions (including rash, pruritus, localized oedema)
Psychiatric disorders - Depressed mood, depression, suicidal ideation

Safety Constraints and Special Populations

Regulatory documents establish several mandatory safety constraints and contraindications:

  • Absolute Contraindications: Avolve is contraindicated in women (especially pregnant or potentially pregnant women), children, adolescents, and individuals with severe hepatic impairment.
  • Fetal Risk: Due to the anti-androgenic effect, exposure to Avolve poses a serious risk of causing abnormalities of the external genitalia in a male fetus. Consequently, pregnant women must not handle the capsules.
  • Blood Donation Restriction: Individuals taking the medication must not donate blood for at least 6 months after the last dose to prevent inadvertent exposure to pregnant transfusion recipients.
  • Serious Warnings: Official labeling includes warnings regarding the potential for an increased incidence of high-grade prostate cancer and the requirement for specific adjustments when interpreting Prostate-Specific Antigen (PSA) levels during monitoring.

Overdose and Emergency Response

Overdose and When to Seek Help

Avolve (Dutasteride) overdose information is primarily defined by the drug's known toxicology profile and the required actions mandated by regulatory bodies for suspected overdose.

Documented Overdose Profile

Regulatory documents indicate that clinical studies involving dutasteride at doses significantly exceeding the prescribed amount (up to 80 times the therapeutic dose) did not identify specific, acute, or additional clinical signs or symptoms. Therefore, no specific acute manifestations of overdose are formally documented in the official prescribing information.

Management Factor Official Statement (Regulatory Basis)
Antidote Availability No specific antidote for dutasteride overdose is known.
Treatment Focus Treatment must be based on symptoms and supportive therapies.
Key Consideration The extremely long terminal elimination half-life (approximately five weeks) must be taken into account for any management plan, necessitating consideration for prolonged observation.

When to Seek Urgent Medical Help

Due to the risks associated with ingesting any amount substantially above the prescribed dose, the official documentation mandates that you seek emergency medical attention immediately upon any suspected overdose. Contact a poison control center for guidance. The necessity for urgent medical care is driven by the need for supportive management and assessment relating to the drug's prolonged presence in the body.

Therapeutic Uses of Avolve

What Avolve Treats: Main Uses and Benefits

A key function of this medication is to provide supportive, symptomatic care in acute situations. Avolve is applied across domains where additional symptomatic support is needed for patients experiencing periods of heightened discomfort or tension. It helps address symptom clusters that may become intense or disruptive, especially those associated with acute or episodic changes. The medication is commonly used across conditions presenting with acute episodes where functional stability becomes affected.

Avolve is relevant for easing certain distressing symptoms, managing functional strain, and providing support during acute symptomatic episodes. It is applied during phases of increased distress or discomfort and is considered relevant when short-term symptomatic assistance is needed. The medication offers symptomatic relief that helps patients cope more steadily with symptom fluctuations.

Quick Fact: Relief for Acute Symptom Manifestations

“Avolve plays a role in managing to support the patient during difficult episodes by easing distress and contributing to improved day-to-day comfort.”

Avolve assists with maintaining functional stability when symptoms interfere with routine activities. This support is relevant in contexts involving heightened systemic burden.

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Avolve

Official regulatory documents strictly define the population groups eligible to use Avolve and those for whom use is contraindicated. The medicine is only indicated for use in adult males (18 years and older).

Category Official Regulatory Statement
Populations for whom use is allowed Adult Males (18+). No dosage adjustment is needed for older adult patients [FDA Label].
Populations for whom use is contraindicated Females/Women. The medicine is contraindicated for use in all women [UK MHRA SmPC].
Pregnant Women or Women of Childbearing Potential. Absolute contraindication due to the risk of fetal harm to a male fetus [DailyMed].
Pediatric Patients (Under 18 Years of Age). Use is absolutely contraindicated [FDA Label].
Condition-specific eligibility rules Severe Hepatic Impairment is a formal contraindication [UK MHRA SmPC]. Mild to moderate hepatic impairment requires caution, as specific dosage recommendations are not established [FDA Label].
Other Restrictions Patients with a known hypersensitivity to Dutasteride or other 5α-reductase inhibitors must not use Avolve [DailyMed].

Connection to the overall eligibility profile

Official prescribing information establishes absolute contraindications based on sex, age, and organ function. Eligibility is confined to adult males, with specific prohibitions against use in all females, children, and individuals with severe liver impairment.

What should I know about interactions with other medicines?

Avolve (dutasteride) is generally metabolized by the CYP3A4 enzyme system. Taking Avolve with medicines that inhibit this enzyme can increase the concentration of Avolve in your blood, potentially increasing the risk of side effects. Conversely, medicines that induce CYP3A4 activity may decrease Avolve levels.

It is essential to inform your doctor or pharmacist of all medicines, vitamins, herbal products, and supplements you are taking. Interactions are possible with both prescription and over-the-counter (OTC) products.

Potential Drug-Drug Interactions

Drug Type Example Medications Potential Effect
Potent CYP3A4 Inhibitors Ritonavir, Ketoconazole, Verapamil, Diltiazem May increase Avolve concentration
CYP3A4 Inducers Rifampicin, Carbamazepine, Phenytoin May decrease Avolve concentration

Other Considerations

  • Grapefruit Juice: Consuming large amounts of grapefruit juice may inhibit CYP3A4 and increase your body's exposure to Avolve. Your healthcare provider may advise you to limit or avoid it.
  • Other 5-alpha reductase inhibitors: Concomitant use with other medications that block 5-alpha reductase (like finasteride) is not recommended, as safety and efficacy data for such combinations are not established.
  • Liver Disease: Patients with liver dysfunction should use caution, as Avolve is extensively metabolized by the liver.

Mechanism of Action

Mechanism of Action: Dual 5alpha-Reductase Inhibition

Avolve, containing Dutasteride, exerts its action through the dual inhibition of the 5alpha-reductase enzyme (5AR). This enzyme exists in two main isoforms, Type 1 and Type 2, both of which are targeted by the molecule. Avolve forms a stable, mechanism-based complex with both 5AR isoforms, resulting in their irreversible inactivation.

This molecular interaction blocks the metabolic conversion of the less active androgen, Testosterone, into the highly potent androgen, Dihydrotestosterone (DHT). The resulting systemic reduction in circulating DHT diminishes the binding of the hormone to nuclear Androgen Receptors in sensitive tissues. This action modifies the local cellular balance, leading to the down-regulation of proliferative genes and an increase in apoptosis (programmed cell death). The physiological result of this altered cellular turnover is a gradual, mechanical reduction in the physical volume of androgen-dependent structures.

Dosage and Administration Information

How to use Avolve

The administration of Avolve, which contains the active ingredient Dutasteride, follows specific usage instructions for continuous, long-term use.


Administration Scope

Feature Guideline
Route of administration Oral route only.
Dosing schedule A single 0.5 mg soft gelatin capsule taken once daily.
Timing in relation to meals May be taken with or without food.
Age-group administration No dose adjustment is required for older adults or individuals with renal impairment.
Missed-dose rule If a dose is missed, it should be omitted, and the next scheduled dose should be taken at the usual time; compensation with a double dose is not permitted.
Special procedural conditions The capsule must be swallowed whole and not chewed, crushed, or opened.

Treatment Protocol

Avolve is intended for long-term continuous administration. Consistent, daily use is essential to the recommended protocol, which often requires treatment for up to six months before the full therapeutic effect is demonstrated. The standard administration approach, utilizing the 0.5 mg oral capsule once daily, defines the structure for adherence to the treatment duration. This regimen does not require dose adjustment for most adult populations, including the elderly or those with mild to moderate kidney issues.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Avolve (Dutasteride)


Evidence for Use in Benign Prostatic Hyperplasia (BPH)

The evidence record for Avolve for men with symptomatic Benign Prostatic Hyperplasia (BPH) is primarily established through large, international Randomized Controlled Trials (RCTs). These trials represent the highest standard of clinical research methodologically and were used in research exploring how symptoms change over time. Researchers applied these studies to adult men, including older adults, who had an enlarged prostate and experienced noticeable urinary symptoms. The studies monitored outcomes related to symptoms reflecting daily functioning or activity level, such as changes in the International Prostate Symptom Score (IPSS), measurements of prostate gland size, and the frequency of events like Acute Urinary Retention (AUR).

The core clinical trials involved observations over intermediate periods, such as one to two years, with extended, long-term follow-up that lasted up to four years. In these studies, researchers monitored patterns related to symptom scores and prostate size measurements over the defined time intervals. Long-term research also monitored the proportional rates of BPH-related events. While the research base is extensive, studies focused on men with specific prostate sizes, meaning data for certain groups remain limited for those with very small prostates or those outside the studied age ranges.


Research Evidence for Androgenetic Alopecia (Male Pattern Hair Loss)

Avolve was studied for its application in men experiencing Androgenetic Alopecia (AGA), or male pattern hair loss. Research focused on measuring physical changes on the scalp as part of research exploring short-term symptom changes linked to AGA. These studies included controlled trials. The key outcomes monitored were direct, physical measurements of hair growth, including changes in total hair count and hair thickness. Research highlights changes measured during the study period using standardized photographic assessments.

The core research evidence for AGA often consists of trials conducted over periods of six months to one year. While some longer-term retrospective analyses exist, long-term effects are not fully established by the same large, randomized clinical trials that support the BPH indication. This means that follow-up durations were limited in many of the key controlled trials for hair loss.


What Is Still Uncertain About the Avolve Research Record

One major area of uncertainty relates to the research that was studied for prostate cancer risk reduction in a large, multi-year trial. While that trial reported an observed lower proportion of overall prostate cancer detection, it also was associated with a proportional change in the detection of high-grade cancers (Gleason 8–10) in a small number of the study participants. This specific finding contributed to the decision by regulatory bodies not to approve Avolve for cancer risk reduction. As with many chronic treatments, long-term effects are not fully established beyond the multi-year trials conducted. Research provides context but not individual predictions, meaning the findings describe group patterns and cannot guarantee how any single individual will respond to the medication.

Key Studies & References

  1. A tale of two trials: The impact of 5α-reductase inhibition on prostate cancer (Review) (discussing the REDUCE trial findings on high-grade cancer)
  2. Dutasteride - StatPearls - NCBI Bookshelf (Summary of indications, dosage, and specific patient populations)

Frequently Asked Questions (FAQ)

Common questions about Avolve (FAQ)


Q: What is Avolve used for besides its main purpose?

Official regulatory documents specify that Avolve is indicated for treating moderate to severe symptoms of benign prostatic hyperplasia (BPH) in men. In addition, the medication is prescribed to help reduce the risk of BPH-related events, such as acute urinary retention (AUR) and the need for BPH-related surgery. This indicates its purpose is focused on managing the progression and complications of BPH.


Q: How quickly can a person generally expect to notice effects from Avolve?

Based on clinical trial data, the full therapeutic benefit of the medicine may be gradual. Studies indicate that consistent, continuous use is typically needed for up to six months before the full effect of the medicine is demonstrated. The established protocol involves continuous daily use.


Q: Does Avolve affect energy levels or cause fatigue?

While not listed as a universally common effect in all studies, some post-marketing reports have noted the occurrence of fatigue or, rarely, extreme fatigue. Concerns regarding this effect can be addressed with a healthcare provider. Official documentation does not consistently classify fatigue as a frequent reaction.


Q: Are there any common supplements or vitamins that should be avoided while taking Avolve?

Official information states that Avolve is broken down in the body by an enzyme system called CYP3A4. Therefore, any herbal products or supplements that significantly inhibit or induce this enzyme may potentially alter the medicine's concentration in the body. While specific common vitamins are not generally listed as contraindications, it is standard procedure to inform a healthcare provider of all supplements being taken.


Q: Why is Avolve described as a 'novel' or 'new class' drug?

The medicine is scientifically recognized as a dual inhibitor because of its mechanism of action. Official sources note that it targets and suppresses both the Type 1 and Type 2 forms of the 5-alpha reductase enzyme. This comprehensive action differentiates it from older medicines that primarily targeted only the Type 2 enzyme.


Q: Is Avolve safe for long-term use?

The medication is established in its regulatory protocol for long-term continuous administration for its approved use. Clinical studies supporting its approval included extended follow-up observations lasting up to four years. However, as is common with many chronic treatments, long-term safety data beyond the duration of these large clinical trials are not fully established.


Q: Is it normal to feel a mild headache when starting Avolve?

Regulatory data and post-marketing reports have noted headache as an adverse reaction. The frequency of this effect is variable across different regulatory documents and studies. Persistent or severe headaches can be discussed with a healthcare provider.


Q: Is there a generic version of Avolve available?

The active ingredient in Avolve is Dutasteride, which is available as a generic medication in many countries and regions. A generic version contains the same active ingredient and is generally considered therapeutically equivalent to the brand-name medicine.


Q: Are there any specific foods that interact with Avolve?

Official interaction warnings highlight grapefruit juice as a food that can interact with the medicine. Because grapefruit juice can inhibit the CYP3A4 enzyme, consuming it may increase the level of Avolve in the bloodstream. Any planned dietary changes should be discussed with a healthcare provider.


Q: Can Avolve affect the results of common lab tests?

Yes, the medicine is known to impact the results of a specific lab test. Official labeling states that Avolve reduces the total serum Prostate-Specific Antigen (PSA) concentration by about 50% after six months of use. This effect necessitates specific adjustments and careful interpretation of PSA levels when monitoring for prostate cancer.


Q: Is Avolve a controlled substance?

No, regulatory bodies do not classify Avolve as a controlled substance. It is regulated as a prescription-only medication due to the serious risks associated with its anti-androgenic mechanism, particularly for certain populations.


Q: Why do some people say Avolve caused them to feel dizzy?

Dizziness is listed in post-marketing reports as an adverse reaction experienced by some users. Although official labeling suggests the medicine is not expected to interfere with the ability to drive or use machinery, individuals experiencing dizziness should be aware of this potential side effect.


Q: How long does Avolve stay in the system after the last dose?

Due to the medicine’s long half-life in the body, regulatory requirements establish a safety constraint regarding blood donation. Individuals who are taking Avolve must not donate blood for at least 6 months following their last dose. This measure is in place to prevent inadvertent exposure of the medicine to pregnant transfusion recipients.


Q: Can Avolve be taken with alcohol?

Regulatory documentation does not list a direct drug interaction between Avolve and alcohol. However, some retrospective analyses have suggested that high alcohol consumption in men using 5-alpha reductase inhibitors may be associated with an increased risk of high-grade prostate cancer detection. Questions about alcohol use can be directed to a healthcare provider.


Q: Why is Avolve sometimes prescribed in combination with other treatments?

Official prescribing information indicates that Avolve is sometimes prescribed in combination with an alpha-blocker (such as tamsulosin) for men managing moderate-to-severe BPH symptoms. This combination is intended to provide a more comprehensive treatment approach, targeting different pathways involved in the condition.


Q: Are there any warnings about driving or operating machinery while using Avolve?

Based on the known pharmacological properties of the medicine, Avolve is not expected to impair the ability to drive or operate machinery. Nevertheless, some post-marketing reports have noted side effects such as dizziness. Individuals should be aware of how they react to the medicine before driving or operating machinery.


Q: Is Avolve known to cause weight gain or loss?

Weight changes are not commonly listed in the most frequent side effect reports. However, weight gain has been noted in some documentation as a rare adverse reaction. Unexpected weight changes can be reviewed by a healthcare professional.


Q: What should be done if someone accidentally takes too much Avolve?

In the event that a person accidentally takes more than the prescribed amount, there is no specific antidote for the medicine. Treatment for overdose would consist of general supportive measures as needed. Studies involving short-term high doses did not indicate any specific, immediate safety concerns beyond the known side effects.


Q: Can I take pain relievers like ibuprofen with Avolve?

Regulatory documentation does not list a specific drug-drug interaction between Avolve and common non-steroidal anti-inflammatory pain relievers like ibuprofen. There is no major known interaction that would typically require avoiding this combination. It is standard care to disclose all medicines and pain relievers to a prescribing physician.


Q: What conditions is Avolve officially approved to treat?

Official regulatory documentation indicates the medicine is approved for the treatment of moderate-to-severe symptomatic Benign Prostatic Hyperplasia (BPH) in men. In some regions, it is also approved for use in combination with an alpha-blocker. Individuals should refer to the label approved in their region for all official indications.


Q: Is it common to have stomach issues when starting Avolve?

While not always classified as common reactions in major clinical trials, some post-marketing reports have noted adverse effects such as nausea and gastrointestinal discomfort. If stomach issues occur and become problematic, a consultation with a healthcare provider is appropriate.


Q: How is Avolve eliminated from the body?

The medicine is extensively broken down by the CYP3A4 enzyme system in the liver. Once metabolized, the compound and its byproducts are primarily eliminated from the body through the feces. Only a very small amount is excreted through the urine.


Q: Does taking Avolve require lifestyle changes?

Official regulatory documents indicate that patients should limit or avoid consuming grapefruit juice because it can interfere with how the body processes the medicine. Beyond this specific dietary instruction, no other major changes to diet or lifestyle are typically required by the official protocol.


Q: What is the maximum duration a person can be on Avolve?

The medicine is established for long-term continuous administration in its approved indications. While clinical trials supporting its use often lasted several years, official prescribing information generally does not specify a maximum time limit for a patient to remain on the medication. Treatment duration is determined based on the patient's condition and the prescribing information.


Q: Does Avolve interact with common antidepressants or anxiety medications?

The medicine is broken down in the liver by the CYP3A4 enzyme system. An interaction is possible if a specific antidepressant or anxiety medication is known to be a strong inhibitor or inducer of this same enzyme. Disclosure of all psychotropic medications to a healthcare provider is standard practice.


Q: Do studies suggest Avolve is effective in all patient populations?

The clinical research base focuses on adult men within specific parameters. For instance, studies supporting the BPH indication concentrated on men with particular prostate sizes, meaning official data for certain patient groups may remain limited. Efficacy results reflect group patterns and cannot guarantee individual outcomes.


Q: How is the safety of Avolve monitored after it is approved?

The safety profile of the medicine is continuously monitored even after approval through established global post-marketing surveillance systems. These ongoing pharmacovigilance programs systematically collect and evaluate reports of suspected adverse events from both healthcare professionals and patients.

How should Avolve be stored and disposed of?

How to Store and Dispose of Avolve?

Avolve (Dutasteride) capsules must be stored at controlled room temperature, typically 68 F to 77 F (20 C to 25 C). The medication must be kept away from light, heat, and moisture, and must not be frozen. The capsules should remain in their original, tightly closed container and must be stored out of the sight and reach of children.

Handling and Disposal

Women who are or may be pregnant must not handle the capsules, and any contact with leaking contents requires immediate washing with soap and water. Disposal of unused or expired Avolve should utilize a drug take-back program. Avolve must not be flushed down the toilet. If a take-back program is unavailable, follow the official procedure of mixing the medicine with an undesirable substance in a sealed bag before disposal in household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Avolve found in:

A-Z Index: